SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 27th Annual ROTH Conference on March 11, 2015 at The Ritz-Carlton Hotel in Laguna Niguel, California.
A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.
Details of the presentation are as follows:
|Event:||27th Annual ROTH Conference|
|Date:||Wednesday, March 11, 2015|
|Place:||The Ritz-Carlton Hotel (Laguna Niguel, CA)|
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-GATM, OncoCEE-BRTM and OncoCEE-LUNGTM test, respectively for gastric, breast and lung cancer and plans to introduce additional CLIA validated tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.
CONTACT: Investor Contact: The Ruth Group David Burke (646) 536-7009 firstname.lastname@example.org